Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Analyzing AD and allergies
An ongoing longitudinal study is investigating whether early and continued treatment of atopic dermatitis with the topical immunomodulator pimecrolimus 1 percent cream (Elidel, Novartis) can prevent future development of asthma and other allergies. The multicenter trial was launched more than three years ago and randomized 1,091 children ages 3 months to 18 months old. An analysis of the demographic features of the study population highlights the value of the cohort for investigating a number of questions about AD and allergies.
Related Videos
Related Content
Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York
September 24th 2023
Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York
September 24th 2023
